Cure HHT would like to share information about the ALN-6400-001 clinical trial, a research study from Alnylam designed to evaluate the safety and effectiveness of an investigational medication for people living with hereditary hemorrhagic telangiectasia (HHT).

There are currently no treatments approved specifically for HHT. This study is an opportunity to move that forward.

Eligibility criteria are specific and the study runs at participating sites. Bring it to your HHT care team before acting on it.

To learn more: write to research@curehht.org.